Angelica Fasolo

Summary

Affiliation: Istituto Nazionale Tumori
Country: Italy

Publications

  1. ncbi Translational research in phase I trials
    Angelica Fasolo
    Medical Oncology, Montabone Unit for New Drugs Development, Istituto Nazionale Tumori Milano, Milan, Italy
    Clin Transl Oncol 11:580-8. 2009
  2. ncbi mTOR inhibitors in the treatment of cancer
    Angelica Fasolo
    Istituto Nazionale dei Tumori, Via Venezian 1, Milano, Italy
    Expert Opin Investig Drugs 17:1717-34. 2008
  3. ncbi Current and future directions in mammalian target of rapamycin inhibitors development
    Angelica Fasolo
    Istituto Nazionale dei Tumori, Via Venezian 1, Milan, Italy
    Expert Opin Investig Drugs 20:381-94. 2011

Detail Information

Publications3

  1. ncbi Translational research in phase I trials
    Angelica Fasolo
    Medical Oncology, Montabone Unit for New Drugs Development, Istituto Nazionale Tumori Milano, Milan, Italy
    Clin Transl Oncol 11:580-8. 2009
    ..This review will focus on the contributions provided by biomarkers to facilitate the development of new targeted therapies...
  2. ncbi mTOR inhibitors in the treatment of cancer
    Angelica Fasolo
    Istituto Nazionale dei Tumori, Via Venezian 1, Milano, Italy
    Expert Opin Investig Drugs 17:1717-34. 2008
    ..Dysregulation of mTOR pathway has been found in many human tumours; therefore, the mTOR pathway is considered an important target for the development of new anticancer drugs...
  3. ncbi Current and future directions in mammalian target of rapamycin inhibitors development
    Angelica Fasolo
    Istituto Nazionale dei Tumori, Via Venezian 1, Milan, Italy
    Expert Opin Investig Drugs 20:381-94. 2011
    ....